Crossmark

Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences

Crossref DOI link: https://doi.org/10.1007/s40266-018-0552-4

Published Online: 2018-05-08

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bolek, Tomáš

Samoš, Matej

Škorňová, Ingrid

Stančiaková, Lucia

Staško, Ján

Galajda, Peter

Kubisz, Peter

Mokáň, Marián
Funding

Funding for this research was provided by:

Agentúra na Podporu Výskumu a Vývoja (16-0020)

Slovak Society of Cardiology (2012 - 2015)
License Information

Text and Data Mining valid from 2018-05-08
More Information

Article History

First Online: 8 May 2018

Compliance with ethical standards

:

: Tomáš Bolek, Matej Samoš, Ingrid Škorňová, Lucia Stančiaková, Ján Staško, Peter Galajda, Peter Kubisz, and Marián Mokáň declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

: This study was funded by a research project of the Slovak Society of Cardiology 2012–2015 and by research project APVV (Slovak Research and Development Agency) 16-0020.

: This research was performed according to ethical standards and was approved by the local ethics committee (Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava).

: The patients agreed to participate in the research and signed informed consent for study participation.